Table 1.
Correlation between expression of OPN and treatment response in cancer patients.
| Cancer Types | Study | Inclusion Year | Sample Size | Cancer Stage | Therapeutic Regimens | Test Method | Treatment Response | n, (%) | OPN Expression | p Value | HR/OR (95% CI) | p Value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low n, (%) | High n, (%) | ||||||||||||
| Cervical SCC | Feng et al. 2018 [13] | January 2015–December 2015 | 116 | IIB-IIIB | IMRT + platinum-based chemotherapy | IHC | Sensitive (CR) | 97 (84%) | 41 (95%) | 56 (77%) | 0.009 | ||
| Resistant (PR + MR + PD) | 19 (16%) | 2 (5%) | 17 (23%) | ||||||||||
| NSCLC | Huang et al. 2018 [14] | March 2010–August 2016 | 73 | I-IV | First-line platinum-based chemotherapy | IHC | PR | 27 (37%) | 12 (38%) | 15 (37%) | 0.038 | 2.326 (1.721–2.616) | 0.005 |
| SD | 38 (52%) | 18 (56%) | 20 (49%) | ||||||||||
| PD | 8 (11%) | 2 (6%) | 6 (15%) | ||||||||||
| OSCC | Luo et al. 2015 [16] | 2006–2012 | 121 | IV | IC + CRRT | IHC | CR/PR | 52 (43%) | 19 (70%) | 33 (35%) | 0.002 | 0.320 (0.120–0.854) | 0.023 |
| SD/PD | 69 (57%) | 8 (30%) | 61 (65%) | ||||||||||
| PC | Aksoy et al. 2017 [17] | 2009–2015 | 30 | IV | TBR | IHC | Responders | 12 (40%) | 1 (20%) | 11 (44%) | 0.622 | ||
| Non-responders | 18 (60%) | 4 (80%) | 14 (56%) | ||||||||||
| LACSCC | Huang et al. 2015 [16] | January 2005–March 2012 | 111 | Ib-Iva (FIGO) | Primary radical radiotherapy | IHC | Radiation-sensitive | 85 (77%) | 59 (95%) | 26 (53%) | <0.001 | ||
| Radiation-resistant | 26 (23%) | 3 (5%) | 23 (47%) | ||||||||||
Abbreviations: NSCLC, non-small-cell lung cancer; OSCC, oral squamous cell carcinoma; PC, prostate cancer; LACSCC, locally advanced cervical squamous cell carcinoma; CR, complete response; MR, improvement; PR, partial response; SD, stable disease; PD, progressive disease; IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; HR, hazard ratio; OR, odds ratio; CI, confidence interval.